NHS reimburses Roche’s Hemlibra in new group of haemophilia patientsNHS England has agreed to reimburse Roche’s Hemlibra (emicizumab) in a new group of patients with haemophilia A, Share XNHS reimburses Roche’s Hemlibra in new group of haemophilia patientshttps://pharmaphorum.com/news/roche-hemlibra-haemophilia/
Roche’s CMO Horning to retire, Lilly’s high-flyer Garraway steps inRoche’s influential chief medical officer Sandra Horning is to retire at the end of the year, the company Share XRoche’s CMO Horning to retire, Lilly’s high-flyer Garraway steps inhttps://pharmaphorum.com/news/roches-cmo-horning-to-retire/
FDA approves Roche’s “tumour agnostic” drug RozlytrekThe FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in Share XFDA approves Roche’s “tumour agnostic” drug Rozlytrekhttps://pharmaphorum.com/news/fda-approves-roches-tumour-agnostic-drug-rozlytrek/
AZ’s lung cancer drug Tagrisso gets boost from first line OS resultsAstraZeneca has announced figures confirming that its Tagrisso extends overall survival in patients with untreated non-small cell lung Share XAZ’s lung cancer drug Tagrisso gets boost from first line OS resultshttps://pharmaphorum.com/news/azs-key-cancer-drug-tagrisso-gets-further-boost-from-os-results/
Roche scores with Tecentriq combo in first-line bladder cancerRoche’s Tecentriq has become the first checkpoint inhibitor to show a benefit in previously-untreated patients with bladder cancer Share XRoche scores with Tecentriq combo in first-line bladder cancerhttps://pharmaphorum.com/news/roche-scores-with-tecentriq-combo-in-first-line-bladder-cancer/
Roche raises 2019 outlook, shrugging off biosimilar threatNew product sales helped Roche to a healthy 9% increase in sales in the first half of the Share XRoche raises 2019 outlook, shrugging off biosimilar threathttps://pharmaphorum.com/news/roche-raises-2019-outlook-shrugging-off-biosimilar-threat/
Sanofi licenses OTC Tamiflu rights for the US marketSanofi has made a bold play to bolster its consumer health business, licensing non-prescription rights to Roche’s influenza Share XSanofi licenses OTC Tamiflu rights for the US markethttps://pharmaphorum.com/news/sanofi-licenses-otc-tamiflu-rights-for-the-us-market/
Genentech extends small-molecule R&D with three platform dealsRoche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its Share XGenentech extends small-molecule R&D with three platform dealshttps://pharmaphorum.com/news/genentech-extends-small-molecule-rd-with-three-platform-deals/
Roche’s Tamiflu successor on target in phase 3 trialA trial of Roche’s successor to flu medicine Tamiflu has met its goal in a phase 3 trial, Share XRoche’s Tamiflu successor on target in phase 3 trialhttps://pharmaphorum.com/news/roches-tamiflu-successor-on-target-in-phase-3-trial/
